AFYX Therapeutics |Reversed Innovation

Hørsholm, Denmark - September 21, 2026 AFYX Therapeutics Granted U.S. Patent for Intranasal Ketamine Treatment of Cluster Headache AFYX Therapeutics A/S today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,1

AFYX Therapeutics Receives EU Approval for Its Low-Dose Oral Misoprostol Tablet for Induction of Labour in 20 European Countries and Northern Ireland. Hørsholm, Denmark - 4 May 2026 AFYX Therapeutics A/S ("AFYX"), a Danish specialty pharmaceutical company

PRESS RELEASE AFYX Therapeutics enters strategic partnership with Adcock Ingram Critical Care for distribution in South Africa and Sub-Saharan Africa. Copenhagen, Denmark - January 22, 2026. AFYX Therapeutics has entered a strategic distribution partnersh

PRESS RELEASE Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment Presented at ESTRO 2025 FOR IMMEDIATE RELEASE - Date: May 5th, 2025 Clinical Study Demonstrates Improved Locoregional Control with Nimo

PRESS RELEASE Hørsholm, Denmark - April 23, 2025 Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX's induction of labor product, Gefena (Misoprostol 25μg tablet). Under this agreement, Lunatus wi

PRESS RELEASE In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers

PRESS RELEASE Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement for France. Hørsholm, Denmark January 13th 2025 - AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing

PRESS RELEASE Hørsholm, Denmark - 6th January 2025 Er-Kim and AFYX Therapeutics A/S announced today a distribution and sales collaboration for two AFYX products. The two companies have entered a mutual sales and distribution collaboration where Er-Kim wil

Danish Biopharmaceutical Leader AFYX Therapeutics A/S Secures DKK 25 million in Funding to Drive Product Development and Global Expansion. PRESS RELEASE Copenhagen, Denmark - December 19, 2025 AFYX Therapeutics A/S, a pioneering Danish biopharmaceutical c